BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loss CM, Teodoro L, Rodrigues GD, Moreira LR, Peres FF, Zuardi AW, Crippa JA, Hallak JEC, Abílio VC. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? Front Pharmacol 2020;11:635763. [PMID: 33613289 DOI: 10.3389/fphar.2020.635763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Visini G, Brown S, Weston-green K, Shannon Weickert C, Chesworth R, Karl T. The effects of preventative cannabidiol in a male neuregulin 1 mouse model of schizophrenia. Front Cell Neurosci 2022;16. [DOI: 10.3389/fncel.2022.1010478] [Reference Citation Analysis]
2 Khalsa JH, Bunt G, Blum K, Maggirwar SB, Galanter M, Potenza MN. Review: Cannabinoids as Medicinals. Curr Addict Rep. [DOI: 10.1007/s40429-022-00438-3] [Reference Citation Analysis]
3 Coccurello R, Marrone MC, Maccarrone M. The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders. Front Pharmacol 2022;13:869606. [DOI: 10.3389/fphar.2022.869606] [Reference Citation Analysis]
4 Carreira LD, Matias FC, Campos MG. Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders. Biomedicines 2022;10:796. [DOI: 10.3390/biomedicines10040796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Stark T, Iannotti FA, Di Martino S, Di Bartolomeo M, Ruda-kucerova J, Piscitelli F, Wotjak CT, D’addario C, Drago F, Di Marzo V, Micale V. Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules 2022;12:108. [DOI: 10.3390/biom12010108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 R.b. Weiss S, Delrahim Howlett K. Cannabidiol: Overview, Complexities, and Opportunities for Behavioral Health. Cannabis in Psychiatric Practice 2022. [DOI: 10.1007/978-3-031-04874-6_3] [Reference Citation Analysis]
7 Stark T, Di Martino S, Drago F, Wotjak CT, Micale V. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol Res 2021;174:105938. [PMID: 34655773 DOI: 10.1016/j.phrs.2021.105938] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]